Influenza Vaccines Market Size & Growth Forecast 2027–2036, By Segments (Vaccine Type, Indication, Age Group, Route of Administration, Distribution Channel), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Influenza Vaccines Market size was more than USD 9.5 billion in 2026 and is set to grow at a 6.18% CAGR between 2027 and 2036, crossing USD 17.3 billion by 2036. The industry revenue for 2027 is estimated at USD 9.99 billion.
Get more details on this report
Request Free Sample ReportInfluenza Vaccines Market Intelligence Snapshot
Regional Market Dynamics
- North America captured 56.02% of the market in 2026, backed by strong immunization infrastructure, established procurement systems, and reliable seasonal vaccination demand through multiple healthcare channels.
- Asia Pacific is forecast to grow at an 8.02% CAGR, supported by expanding immunization access, broader vaccination outreach, and increasing healthcare participation in preventive seasonal influenza vaccination programs.
Segment Momentum
- Inactivated vaccines accounted for 87.34% of the market in 2026, supported by their established role in immunization programs and well-developed manufacturing, distribution, and administration pathways.
- Quadrivalent vaccines held an 82.43% share in 2026 and are also the fastest-growing segment, benefiting from broader strain coverage and strong alignment with seasonal vaccination planning requirements.
Market Expansion Drivers
- Rising global influenza incidence strengthening annual vaccination demand across adult populations.
- Government-backed immunization campaigns and surveillance programs supporting vaccine uptake expansion.
- Advancements in mRNA and combination vaccines improving efficacy and manufacturing responsiveness.
Leading Market Participants
- Top companies in the influenza vaccines market include Sanofi S.A. (France), GSK plc (United Kingdom), CSL Limited (Australia), AstraZeneca plc (United Kingdom), Pfizer Inc. (United States), Seqirus Ltd. (United Kingdom), Moderna, Inc. (United States), Merck & Co., Inc. (United States), Sinovac Biotech Ltd. (China), Viatris Inc. (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 9.5 billion
- 2027 Estimated Market Size: USD 9.99 billion.
- Projected Market Size: USD 17.3 billion by 2036
- Growth Forecast: 6.18% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Inactivated (Vaccine Type) | Quadrivalent (Indication) | Adult (Age Group) | Injection (Route of Administration) | Hospitals & Pharmacies (Distribution Channel)
- Emerging Opportunity Segment: Live Attenuated (Vaccine Type) | Quadrivalent (Indication) | Pediatric (Age Group) | Nasal Spray (Route of Administration) | Government & Institutional Supply (Distribution Channel)
Market Growth Drivers and Industry Trends
Rising global influenza incidence strengthening annual vaccination demand across adult populations
Rising incidence of influenza is reinforcing the need for recurring immunization, particularly among adult populations exposed to seasonal outbreaks and associated health risks. The influenza vaccines market will benefit from continued demand for annual vaccination as immunity may decline over time and circulating influenza strains can vary between seasons. Greater awareness of preventive healthcare and the importance of vaccination among adults can also encourage more consistent participation in seasonal immunization programs, supporting demand across healthcare delivery channels.
Government-backed immunization campaigns and surveillance programs supporting vaccine uptake expansion
Government-backed vaccination initiatives and influenza surveillance activities are strengthening public health infrastructure around seasonal disease prevention. Such programs support the influenza vaccines market by improving population awareness, identifying patterns of influenza circulation, and facilitating targeted immunization efforts among groups considered more vulnerable to complications. Coordinated vaccination campaigns can also improve access through public healthcare facilities and community-based programs, while surveillance data helps health authorities plan vaccination activities around evolving seasonal disease patterns.
Advancements in mRNA and combination vaccines improving efficacy and manufacturing responsiveness
Technological progress in vaccine development is creating opportunities to improve how influenza vaccines address changing viral strains and evolving immunization requirements. Advancements in mRNA and combination technologies will propel the influenza vaccines market by enabling researchers to explore more adaptable vaccine platforms and broader protection approaches. These technologies can also support responsive manufacturing strategies, while combination formulations may simplify vaccination by addressing multiple relevant strains or targets within a single product.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising global influenza incidence strengthening annual vaccination demand across adult populations | 2.00% | High | North America, Europe, Asia Pacific | High | Near Term |
| Government-backed immunization campaigns and surveillance programs supporting vaccine uptake expansion | 1.80% | High | North America, Europe, Asia Pacific | High | Mid Term |
| Advancements in mRNA and combination vaccines improving efficacy and manufacturing responsiveness | 1.50% | High | North America, Europe | Emerging | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America accounted for a 56.02% share of the influenza vaccines market in 2026, supported by established immunization infrastructure, strong public health systems, and broad awareness of seasonal influenza prevention. Demand is reinforced by routine vaccination programs, healthcare-provider recommendations, and the continued emphasis on reducing influenza-related healthcare burdens. Advanced vaccine distribution networks, well-developed clinical capabilities, and strong preparedness for seasonal outbreaks further underpin the region's market position.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is the fastest-growing region, driven by expanding healthcare access, improving immunization infrastructure, and rising awareness of preventive healthcare. Governments and healthcare providers are placing greater emphasis on vaccination as part of broader infectious disease prevention strategies, encouraging wider access to influenza immunization. Strengthening cold-chain capabilities, growing healthcare investment, and increasing public awareness are supporting broader vaccine adoption across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Public Health Procurement FocusGermany supports the influenza vaccines market through coordinated vaccination campaigns and structured procurement practices. Demand in Germany increasingly reflects interest in high-value vaccine formulations that improve protection for aging populations and high-risk patient groups.
France 🇫🇷
Preventive Care ExpansionFrance continues to strengthen influenza vaccination through preventive healthcare initiatives and broader public awareness efforts. The influenza vaccines market in France benefits from policies encouraging higher vaccination uptake among vulnerable populations and healthcare professionals.
Italy 🇮🇹
Regional Vaccination CoordinationItaly focuses on improving influenza vaccine accessibility through regional healthcare systems and coordinated immunization campaigns. The influenza vaccines market in Italy reflects continued attention to protecting elderly populations while maintaining stable vaccine procurement across public health networks.
Japan 🇯🇵
Aging Population ProtectionJapan prioritizes influenza vaccination strategies that address the needs of its older population while maintaining consistent immunization coverage. The influenza vaccines market in Japan benefits from strong clinical standards and continued evaluation of improved vaccine formulations.
South Korea 🇰🇷
Domestic Vaccine DevelopmentSouth Korea strengthens the influenza vaccines market by investing in local vaccine production and expanding national immunization capabilities. The country increasingly supports innovation that enhances supply resilience and responds efficiently to seasonal vaccination requirements.
United States 🇺🇸
Seasonal Immunization InnovationThe U.S. influenza vaccines market emphasizes broad seasonal immunization programs, expanded manufacturing capacity, and the adoption of advanced vaccine technologies. Healthcare providers and public agencies in the U.S. continue to prioritize reliable supply and improved vaccine effectiveness across diverse population groups.
Segment Leadership and Growth Trends
Influenza Vaccines Market Share (%), by Vaccine Type, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportVaccine Type Segment Analysis: Inactivated (Largest Segment) vs Live Attenuated (Fastest-Growing Segment)
The inactivated segment led the influenza vaccines market, accounting for an 87.34% share in 2026. Its dominant position is supported by widespread use across diverse patient populations and established integration into seasonal immunization programs. Inactivated influenza vaccines are commonly administered through established healthcare settings and benefit from broad acceptance among healthcare providers and public health systems. Ongoing efforts to strengthen preventive healthcare and reduce the burden of seasonal influenza continue to support the segment's substantial market presence.
The live attenuated segment is the fastest-growing vaccine type segment, driven by growing interest in alternative vaccine formulations and delivery approaches. Its appeal is supported by the potential for needle-free administration in suitable populations, which can improve convenience and acceptance for some recipients. Increasing emphasis on expanding vaccination coverage, along with continued research into vaccine technologies and more accessible immunization strategies, is expected to support the segment's growth.
Indication Segment Analysis: Quadrivalent (Largest & Fastest-Growing Segment)
The quadrivalent segment dominated the influenza vaccines market with an 82.43% share in 2026 and was also the fastest-growing indication segment. Its strong position is driven by the broad protection offered through coverage against multiple influenza strains, making it a key component of contemporary seasonal vaccination strategies. Growing efforts to improve population-level influenza prevention, rising awareness of vaccination benefits, and the continued emphasis on reducing the impact of seasonal outbreaks are supporting demand. The segment's alignment with evolving immunization practices and healthcare priorities further contributes to its combined leadership and growth momentum.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Vaccine Type | Inactivated, Live Attenuated | Inactivated | Live Attenuated |
| Indication | Quadrivalent, Trivalent | Quadrivalent | Quadrivalent |
| Age Group | Pediatric, Adult | Adult | Pediatric |
| Route of Administration | Injection, Nasal Spray | Injection | Nasal Spray |
| Distribution Channel | Hospitals & Pharmacies, Government & Institutional Supply, Other | Hospitals & Pharmacies | Government & Institutional Supply |
Competitive Landscape and Market Positioning
Leading companies in the influenza vaccines market:
1. Sanofi S.A. (France)
2. GSK plc (United Kingdom)
3. CSL Limited (Australia)
4. AstraZeneca plc (United Kingdom)
5. Pfizer Inc. (United States)
6. Seqirus Ltd. (United Kingdom)
7. Moderna Inc. (United States)
8. Merck & Co. Inc. (United States)
9. Sinovac Biotech Ltd. (China)
10. Viatris Inc. (United States)
The influenza vaccines market is evolving through continuous advancements in vaccine technologies, including cell-based production and next-generation immunization platforms. Manufacturers are strengthening research capabilities to improve vaccine effectiveness and accelerate response to seasonal virus mutations. Investments in scalable production technologies and distribution efficiency are also becoming critical competitive priorities within the influenza vaccines market.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Sanofi S.A. (France) | |||||||
| GSK plc (United Kingdom) | |||||||
| CSL Limited (Australia) | |||||||
| AstraZeneca plc (United Kingdom) | |||||||
| Pfizer Inc. (United States) | |||||||
| Seqirus Ltd. (United Kingdom) | |||||||
| Moderna Inc. (United States) | |||||||
| Merck & Co. Inc. (United States) | |||||||
| Sinovac Biotech Ltd. (China) | |||||||
| Viatris Inc. (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Pan American Health Organization (PAHO) | May-26 | PAHO reached a regional supply agreement to reserve pandemic influenza vaccine doses for countries across Latin America and the Caribbean. This strategic collaboration enhances regional vaccine distribution logistics and strengthens collective pandemic preparedness frameworks for the Latin American market. |
| Moderna | Mar-26 | Moderna achieved a regulatory milestone as the European Medicines Agency provided support for its combined influenza-COVID mRNA vaccine candidate. This advancement signals progress in the commercialization of next-generation, high-efficacy respiratory vaccines in Europe. |
| European Commission | Feb-26 | The European Commission launched a €225 million pre-commercial procurement initiative focused on developing next-generation influenza vaccines. The program aims to accelerate innovation in vaccine technologies capable of providing broader protection and facilitating faster manufacturing response times to emerging pandemic strains. |
| Sanofi | Jan-26 | Sanofi discontinued its mRNA seasonal influenza vaccine program. The company remains committed to the influenza market, shifting its strategic focus toward the continued clinical development of an mRNA-based H5 influenza vaccine candidate specifically tailored for pandemic preparedness. |
| CSL Seqirus | Dec-25 | CSL Seqirus inaugurated a $1 billion manufacturing facility in Melbourne. This major infrastructure investment is dedicated to the production of cell-based influenza vaccines and antivenoms, substantially increasing regional manufacturing capacity and enhancing the resilience of the global influenza vaccine supply chain. |
| Moderna | Dec-25 | Moderna secured up to $54 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to accelerate the Phase 3 clinical development of its mRNA-based pandemic influenza vaccine candidate, bolstering global efforts to prepare against potential avian influenza outbreaks. |
| Merck | Nov-25 | Merck entered a definitive agreement to acquire Cidara Therapeutics' long-acting influenza prophylactic candidate, CD388, for approximately $9.2 billion. Currently in Phase 3 development, the asset is positioned to provide prophylactic coverage for high-risk populations, representing a significant strategic investment in the influenza prevention landscape. |
| AstraZeneca | Jan-25 | AstraZeneca cancelled a planned £450 million expansion of its vaccine manufacturing facility in Liverpool. The decision followed a reduction in projected government funding, resulting in the termination of planned production capacity increases for its vaccine portfolio. |
| CSL Seqirus | Sep-24 | CSL Seqirus was awarded a $121.4 million contract by BARDA to supply adjuvant material sufficient for approximately 40 million pandemic influenza vaccine doses. This procurement strengthens the U.S. government’s strategic stockpile and regional preparedness efforts against potential pandemic-level influenza threats. |
| Sanofi | May-24 | Sanofi finalized a strategic partnership with Novavax, involving a $500 million upfront payment to co-commercialize the Novavax COVID-19 vaccine and collaborate on the development of future combination influenza-COVID-19 vaccine candidates utilizing Novavax’s Matrix-M adjuvant technology. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Influenza Vaccines Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Funding Source | Public/Government Funding, Private Insurance Funding, Out-of-Pocket Funding |
| Immunization Program Type | Routine Seasonal Immunization Programs, High-Risk Population Programs, Mass/Public Health Campaigns |
| Vaccination Setting | Hospital-Based Vaccination, Primary Care & Physician Offices, Community & Retail Vaccination, Workplace & Institutional Vaccination |
Influenza Vaccines Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| National Immunization Program Opportunity Assessment |
|
| Vaccine Procurement and Tender Intelligence |
|
| Pandemic Preparedness and Stockpiling Strategy |
|
Need a different cut of the data?
Request Custom ResearchWhat is the current revenue of the influenza vaccines market?
What is the forecasted size of the influenza vaccines industry?
How are government immunization programs supporting growth in the influenza vaccines market?
How are vaccine technology advancements influencing the influenza vaccines market?
Why do Inactivated vaccines dominate the influenza vaccines market?
Which indication segment leads growth in the influenza vaccines market?
What supports North America's leadership in the influenza vaccines market?
Why is Asia Pacific emerging as the fastest-growing influenza vaccines market?
Which companies are driving growth in the influenza vaccines landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization